CLNN - Clene Inc. Stock Price, Fair Value and News

0.37USD-0.02 (-5.13%)Market Closed

Market Summary

USD0.37-0.02

Market Closed

-5.13%

CLNN Stock Price

View Fullscreen

CLNN RSI Chart

CLNN Valuation

Market Cap

47.5M

Price/Earnings (Trailing)

-0.97

Price/Sales (Trailing)

76.65

EV/EBITDA

-0.61

Price/Free Cashflow

-1.69

CLNN Price/Sales (Trailing)

CLNN Profitability

Operating Margin

78.71%

EBT Margin

-7873.23%

Return on Equity

-1.1K%

Return on Assets

-108.31%

Free Cashflow Yield

-59.17%

CLNN Fundamentals

CLNN Revenue

Revenue (TTM)

620.0K

Rev. Growth (Yr)

-31.78%

Rev. Growth (Qtr)

-57.06%

CLNN Earnings

Earnings (TTM)

-48.8M

Earnings Growth (Yr)

5.86%

Earnings Growth (Qtr)

-8.92%

Breaking Down CLNN Revenue

Last 7 days

-5.1%

Last 30 days

8.8%

Last 90 days

-19.6%

Trailing 12 Months

-59.8%

How does CLNN drawdown profile look like?

CLNN Financial Health

Current Ratio

1.23

CLNN Investor Care

Shares Dilution (1Y)

63.83%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	620.0K	0	0	0
2023	550.0K	784.0K	718.0K	654.0K
2022	540.0K	374.0K	438.0K	473.0K
2021	349.0K	541.0K	553.0K	723.0K
2020	0	0	0	206.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Clene Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	general resonance llc	sold	-5,148	0.396	-13,000	-
Apr 30, 2024	general resonance llc	sold	-5,415	0.4166	-13,000	-
Apr 24, 2024	general resonance llc	sold	-3,278	0.3278	-10,000	-
Apr 09, 2024	general resonance llc	sold	-8,674	0.385533	-22,500	-
Nov 10, 2023	matlin david j	bought	102,501	0.41	250,002	-
Jun 26, 2023	etherington robert dee	bought	20,250	0.81	25,000	chief executive officer
Jun 26, 2023	stevens john henry	bought	253,164	0.8	316,455	-
Jun 16, 2023	mosca alison	bought	1,915,500	0.8	2,394,380	-
Jun 16, 2023	gay jonathon	bought	84,500	0.8	105,625	-

Which funds bought or sold CLNN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-6,656	-	-%
May 16, 2024	AWM Investment Company, Inc.	sold off	-100	-798,214	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-63.13	-7,680	8,620	-%
May 15, 2024	STATE STREET CORP	unchanged	-	16,493	54,471	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	43,616	144,055	-%
May 15, 2024	Laird Norton Wetherby Trust Company, LLC	unchanged	-	34,593	114,254	0.01%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	51.05	7,402	13,735	-%
May 15, 2024	ADAR1 Capital Management, LLC	sold off	-100	-3,411	-	-%
May 15, 2024	AE Wealth Management LLC	sold off	-100	-91,078	-	-%
May 15, 2024	Alyeska Investment Group, L.P.	reduced	-71.89	-298,637	201,695	-%

Are Funds Buying or Selling CLNN?

Are funds buying CLNN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLNN

No. of Funds

Unveiling Clene Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	mosca alison	9.6%	12,857,926	SC 13G/A
Feb 14, 2024	awm investment company, inc.	9.2%	12,691,213	SC 13G
Feb 14, 2024	citadel advisors llc	4.3%	6	SC 13G/A
Feb 13, 2024	vivo opportunity fund holdings, l.p.	7.0%	12,500,000	SC 13G/A
Sep 11, 2023	ugwumba chidozie	19.9%	28,018,908	SC 13G
Jul 03, 2023	citadel advisors llc	5.7%	6	SC 13G
Jun 28, 2023	vivo opportunity fund holdings, l.p.	9.99%	17,737,800	SC 13G
Jun 20, 2023	matlin david j	5.6%	7,146,990	SC 13D/A
Feb 21, 2023	matlin david j	7.6%	5,604,362	SC 13D/A
Feb 17, 2023	foley & lardner/ fa	7.6%	5,601,862	SC 13D/A

Recent SEC filings of Clene Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	4	Insider Trading
May 08, 2024	424B5	Prospectus Filed
May 08, 2024	8-K	Current Report
May 01, 2024	4	Insider Trading
Apr 26, 2024	8-K	Current Report
Apr 17, 2024	ARS	ARS
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	8-K	Current Report
Apr 16, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Clene Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Clene Inc. News

Latest updates

Clene Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-57.1%	73,000	170,000	108,000	269,000	107,000	234,000	174,000	35,000	30,000	199,000	110,000	201,000	213,000	29,000	98,000	9,000	70,000
Cost Of Revenue	-57.9%	16,000	38,000	12,000	66,000	5,000	7,000	19,000	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-7.9%	9,305,000	10,100,000	9,650,000	10,605,000	10,839,000	11,907,000	9,979,000	13,630,000	13,366,000	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	9,979,000	13,630,000	13,366,000	14,257,000	10,560,000	13,976,000	11,908,000	5,989,000	5,789,000	4,570,000	4,072,000
S&GA Expenses	-100.0%	-	3,389,000	3,666,000	3,924,000	3,439,000	4,129,000	3,557,000	4,464,000	4,786,000	5,257,000	4,400,000	6,949,000	5,390,000	1,528,000	1,795,000	1,016,000	812,000
R&D Expenses	-12.0%	5,869,000	6,673,000	5,972,000	6,615,000	7,395,000	7,771,000	6,403,000	9,166,000	8,580,000	9,523,000	6,146,000	6,472,000	6,275,000	4,454,000	3,994,000	3,554,000	3,202,000
EBITDA Margin	-3.4%	-68.34	-66.12	-48.10	-55.65	-42.78	-54.13	-50.87	44.91	31.76	-13.15	-20.40	-93.25	-	-	-	-	-
Interest Expenses	3.7%	1,244,000	1,200,000	1,188,000	1,104,000	1,066,000	906,000	857,000	751,000	782,000	-950,000	80,000	26,000	551,000	-	-	190,000	51,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-215,000	-69,000	-72,000	-72,000	-	-	-	-
Earnings Before Taxes	-8.9%	-11,080,000	-10,173,000	-2,418,000	-25,143,000	-11,770,000	-1,054,000	-10,976,000	-4,534,000	-13,354,000	4,208,000	28,875,000	-3,423,000	-39,828,000	1,184,000	-10,295,000	-5,819,000	-3,941,000
EBT Margin	-4.0%	-78.73	-75.69	-56.25	-62.43	-51.52	-63.25	-56.29	40.63	30.20	-14.06	-23.86	-96.79	-	-	-	-	-
Net Income	-8.9%	-11,080,000	-10,173,000	-2,418,000	-25,143,000	-11,770,000	-1,054,000	-10,976,000	-4,534,000	-13,354,000	4,423,000	28,944,000	-3,351,000	-39,756,000	778,000	-10,295,000	-5,819,000	-3,941,000
Net Income Margin	-4.0%	-78.73	-75.69	-56.25	-62.43	-51.52	-63.25	-55.80	41.39	30.86	-13.47	-24.20	-97.27	-	-	-	-	-
Free Cashflow	1.7%	-7,093,000	-7,215,000	-6,847,000	-6,961,000	-9,478,000	-9,412,000	-10,140,000	-10,618,000	-14,020,000	-10,253,000	-7,559,000	-8,717,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-13.9%	45.00	52.00	60.00	68.00	40.00	44.00	36.00	45.00	53.00	63.00	73.00	73.00	59.00	68.00	15.00
Current Assets	-17.4%	32.00	39.00	46.00	53.00	25.00	29.00	21.00	32.00	42.00	55.00	65.00	68.00	53.00	63.00	9.00
Cash Equivalents	-24.4%	22.00	29.00	42.00	49.00	18.00	18.00	7.00	7.00	13.00	50.00	61.00	63.00	48.00	59.00	9.00
Inventory	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net PPE	-	-	-	-	-	-	-	10.00	8.00	6.00	5.00	4.00	4.00	4.00	4.00	4.00
Liabilities	4.8%	41.00	39.00	39.00	46.00	42.00	41.00	45.00	45.00	51.00	50.00	67.00	99.00	95.00	68.00	10.00
Current Liabilities	3.4%	26.00	25.00	15.00	6.00	17.00	14.00	6.00	8.00	5.00	6.00	5.00	5.00	4.00	12.00	4.00
LT Debt, Current	3.4%	5.00	5.00	-	-	-	-	-	-	-	-	-	-	-	6.00	-
Shareholder's Equity	-68.2%	4.00	13.00	21.00	22.00	-1.63	3.00	-	-	2.00	13.00	6.00	-	-	0.00	-
Retained Earnings	-4.6%	-253	-242	-232	-230	-205	-193	-192	-181	-176	-163	-167	-196	-193	-153	-69.57
Additional Paid-In Capital	0.8%	258	256	254	251	203	196	183	181	178	176	173	170	157	154	2.00
Shares Outstanding	0.0%	128	128	128	128	78.00	75.00	64.00	63.00	63.00	62.00	62.00	61.00	-	-	-
Float	-	-	-	-	78.00	-	-	-	85.00	-	-	-	360	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	1.3%	-7,082	-7,172	-6,799	-7,000	-9,200	-7,711	-8,486	-9,730	-13,084	-9,582	-7,318	-8,500	-9,200	-5,800	-7,698	-2,151	-3,251	-
Share Based Compensation	-1.7%	2,013	2,047	2,396	2,451	2,223	2,029	2,098	2,184	2,202	2,439	2,425	4,255	3,265	207	209	174	171	-
Cashflow From Investing	101.1%	71.00	-6,212	-48.00	39.00	4,722	2,282	8,411	3,665	-24,522	-671	-241	-217	-203	-118	-75.00	-171	-23.00	-
Cashflow From Financing	-5.6%	-19.00	-18.00	-237	37,830	4,588	16,374	92.00	548	235	-18.00	5,232	23,794	-1,896	28,170	37,696	2,121	1,547	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLNN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 73	$ 107
Operating expenses:
Cost of revenue	16	5
Research and development	5,869	7,395
General and administrative	3,420	3,439
Total operating expenses	9,305	10,839
Loss from operations	(9,232)	(10,732)
Other income (expense), net:
Interest income	359	172
Interest expense	(1,244)	(1,066)
Commitment share expense	0	(399)
Change in fair value of common stock warrant liabilities	(1,309)	0
Change in fair value of Clene Nanomedicine contingent earn-out liability	53	(55)
Change in fair value of Initial Stockholders contingent earn-out liability	7	(7)
Research and development tax credits and unrestricted grants	286	314
Other income, net	0	3
Total other income (expense), net	(1,848)	(1,038)
Net loss before income taxes	(11,080)	(11,770)
Income tax benefit	0	0
Net loss	(11,080)	(11,770)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	(4)	14
Foreign currency translation adjustments	(55)	4
Total other comprehensive income (loss)	(59)	18
Comprehensive loss	$ (11,139)	$ (11,752)
Net loss per share – basic and diluted (in dollars per share)	$ (0.09)	$ (0.15)
Weighted average common shares used to compute basic and diluted net loss per share (in shares)	128,427,231	76,049,665
Product [Member]
Revenue:
Total revenue	$ 44	$ 64
Royalty [Member]
Revenue:
Total revenue	$ 29	$ 43

CLNN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 21,732	$ 28,821
Marketable securities	6,178	6,179
Accounts receivable	64	143
Inventory	37	37
Prepaid expenses and other current assets	4,100	3,672
Total current assets	32,111	38,852
Restricted cash	58	58
Operating lease right-of-use assets	4,046	4,168
Property and equipment, net	8,854	9,263
TOTAL ASSETS	45,069	52,341
Current liabilities:
Accounts payable	1,645	1,504
Accrued liabilities	3,905	3,720
Operating lease obligations, current portion	599	576
Finance lease obligations, current portion	7	27
Notes payable, current portion	14,987	14,627
Convertible notes payable, current portion	5,042	4,876
Total current liabilities	26,185	25,330
Operating lease obligations, net of current portion	4,720	4,903
Notes payable, net of current portion	1,820	1,894
Convertible notes payable, net of current portion	5,265	5,258
Common stock warrant liabilities	2,790	1,481
Clene Nanomedicine contingent earn-out liability	22	75
Initial Stockholders contingent earn-out liability	3	10
TOTAL LIABILITIES	40,805	38,951
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.0001 par value: 300,000,000 and 300,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 128,433,721 and 128,422,851 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	13	13
Additional paid-in capital	257,914	255,901
Accumulated deficit	(253,803)	(242,723)
Accumulated other comprehensive income	140	199
TOTAL STOCKHOLDERS’ EQUITY	4,264	13,390
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 45,069	$ 52,341

About Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CEO	Mr. Robert Etherington MBA
WEBSITE	https://clene.com
INDUSTRY	Biotechnology
EMPLOYEES	75

Clene Inc. Frequently Asked Questions

What is the ticker symbol for Clene Inc.? What does CLNN stand for in stocks?

CLNN is the stock ticker symbol of Clene Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Clene Inc. (CLNN)?

As of Fri May 17 2024, market cap of Clene Inc. is 47.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLNN stock?

You can check CLNN's fair value in chart for subscribers.

What is the fair value of CLNN stock?

You can check CLNN's fair value in chart for subscribers. The fair value of Clene Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Clene Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLNN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Clene Inc. a good stock to buy?

The fair value guage provides a quick view whether CLNN is over valued or under valued. Whether Clene Inc. is cheap or expensive depends on the assumptions which impact Clene Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLNN.

What is Clene Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CLNN's PE ratio (Price to Earnings) is -0.97 and Price to Sales (PS) ratio is 76.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLNN PE ratio will change depending on the future growth rate expectations of investors.